Fibrinogen alpha amyloidosis: insights from proteomics
Authors:
- 13 August 2019
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Proteomics
- Vol. 16 (9) , 783-793
Abstract
Introduction: Systemic amyloidosis is a diverse group of diseases that, although rare, pose a serious health issue and can lead to organ failure and death. Amyloid typing is essential in determining the causative protein and initiating proper treatment. Mass spectrometry-based proteomics is currently the most sensitive and accurate means of typing amyloid. Areas covered: Amyloidosis can be systemic or localized, acquired or hereditary, and can affect any organ or tissue. Diagnosis requires biopsy, histological analysis, and typing of the causative protein to determine treatment. The kidneys are the most commonly affected organ in systemic disease. Fibrinogen alpha chain amyloidosis (AFib) is the most prevalent form of hereditary renal amyloidosis. Select mutations in the fibrinogen Aα (FGA) gene lead to AFib. Expert commentary: Mass spectrometry is currently the most specific and sensitive method for amyloid typing. Identification of the mutated fibrinogen alpha chain can be difficult in the case of ‘private’ frameshift mutations, which dramatically change the sequences of the expressed fibrinogen alpha chain. A combination of expert pathologist review, mass spectrometry, and gene sequencing can allow for confident diagnosis and determination of the fibrinogen alpha chain mutated sequence.Keywords
This publication has 108 references indexed in Scilit:
- Mechanisms of fibrin polymerization and clinical implicationsBlood, 2013
- Validation of a robust proteomic analysis carried out on formalin‐fixed paraffin‐embedded tissues of the pancreas obtained from mouse and humanProteomics, 2012
- Laser microdissection and mass spectrometry–based proteomics aids the diagnosis and typing of renal amyloidosisKidney International, 2012
- Toward deciphering proteomes of formalin‐fixed paraffin‐embedded (FFPE) tissuesProteomics, 2012
- Amyloidosis: Pathogenesis and New Therapeutic OptionsJournal of Clinical Oncology, 2011
- Hereditary fibrinogen A α-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantationBlood, 2010
- Fibrinogen amyloidosis: the clot thickens!Blood, 2010
- Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen Aα-Chain AmyloidosisJournal of the American Society of Nephrology, 2009
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006
- Variant apolipoprotein AI as a major constituent of a human hereditary amyloidBiochemical and Biophysical Research Communications, 1988